News for Tryp Therapeutics Inc. (TRYPF)

Tryp Therapeutics, Inc. announces, that it has filed amended financial statements for the six months ended February 29, 2024 , along with the corresponding Management Discussion & Analysis . The...

Tryp Therapeutics Inc. has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm Limited ACN 163 765 991 have approved the previously announced plan of...

Effective immediately, Tryp Therapeutics Inc. will be reinstated for trading. The Company has rectified the situation that gave rise to the suspension. ...

Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones.

Canadian psychedelics biotech Tryp Therapeutics Inc. has entered into an agreement with Australian publicly-trading drug vehicle developer Exopharm Ltd. for the acquisition of 100% of Tryp’s issued and outstanding common shares.

/PRNewswire/ -- The binge-eating disorder treatment market size is expected to increase by USD 578.04 million from 2022 to 2027, registering a CAGR of 7.26%,...

Tryp Therapeutics Inc. reported earnings results for the third quarter and nine months ended May 31, 2023. For the third quarter, the company reported net loss was CAD 0.655799 million compared to CAD...

Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital (MGH) on the effects of psilocybin-assisted psychotherapy for adults with Irritable B

Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalgia and chronic pain as the initially targeted indications.

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental health conditions and how clinical dat

Company to be in San Francisco January 8-11, 2023, during 41st Annual J.P. Morgan Health Care Conference

KELOWNA, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) —

KELOWNA, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company...

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on...

Pune, Oct. 27, 2022 (GLOBE NEWSWIRE) -- "Psychedelic Drugs Market" Insights 2022 By Types, Applications, Regions and Forecast to 2028. The global...

Enables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments

KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) —

KELOWNA, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a clinical-stage...